Sanofi Q3 2020 business EPS growth of 8.8% at CER

We achieved strong growth in our treatment for type 2 inflammation disorders and vaccines during Q3. We helped transform the lives of thousands of patients and reduced the spread of vaccine-preventable diseases, even as we continue to fight COVID-19.

Paul Hudson
Chief Executive Officer

Q3 2020 infographic

Paul Hudson comments on Q3 2020 results